What can we learn from COVID-19 that could protect us from pandemic influenza? What fresh insights could speed development of next-generation influenza vaccines? The Influenzer Initiative explores these questions in publications ranging from a comprehensive white paper to topic-specific commentaries.
White Paper and Presentation
The vaccine R&D ecosystem after COVID-19: paradigm shifts or business as usual in tackling future influenza pandemic threats?
The urgent scientific and technological response to COVID-19—marked by unprecedented collaboration across disciplines and sectors, and fueled by a vast, diverse funding network—has rapidly altered the vaccine research and development ecosystem. To distill lessons to guide future efforts against pandemic disease threats, including the likely emergence of a novel, virulent influenza virus, we sought to identify and assess novel and effective approaches to vaccine development employed in this crisis. What worked, and what barriers to progress persist?
Our white paper examines the results of information-gathering activities aimed at harnessing COVID-era insights to inform and inspire next-generation influenza vaccine development. To assess the changing R&D landscape, we conducted video interviews, a broad stakeholder survey, and a scientific literature and policy review, gathering perspectives from professionals and thought leaders in the life sciences, vaccinology, pandemic preparedness, vaccine regulation, policy and funding. Combined, they provide a timely review of this crucial period in vaccine innovation, and its implications for preventing future pandemics.
The vaccine R&D ecosystem after COVID-19
Marissa Malchione presented findings from our white paper at the European Scientific Working Group on Influenza’s virtual conference on December 6, 2020. Watch her talk and Q&A session.